[Duodenal gastrointestinal stromal tumor (GIST) with deletion in exon 11 of c-kit treated with emergency pancreaticoduodenectomy due to massive bleeding: a case report].
暂无分享,去创建一个
T. Takayama | S. Tamura | N. Muguruma | Kaizo Kagemoto | K. Naruse | Y. Mitsui | Shuji Inoue | S. Yamasaki | Tatsuzo Itagaki
[1] Ji Li,et al. Duodenal gastrointestinal stromal tumor: clinicopathological characteristics, surgical outcomes, long term survival and predictors for adverse outcomes. , 2013, American journal of surgery.
[2] J. Blay,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[3] C. Raut,et al. Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-Center Study , 2012, Annals of Surgical Oncology.
[4] Aki Vehtari,et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.
[5] 亘 高山,et al. 選択的血管造影塞栓術施行後,待機的に膵頭十二指腸切除術を施行した出血性十二指腸gastrointestinal stromal tumorの1例 , 2012 .
[6] C. Ferreira,et al. Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors. , 2010, Anticancer research.
[7] T. Tsujinaka,et al. Survival Analysis of Patients With Duodenal Gastrointestinal Stromal Tumors , 2010, Journal of clinical gastroenterology.
[8] C. Antonescu,et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.
[9] M. Heinrich,et al. Gastrointestinal stromal tumour , 2007, The Lancet.
[10] J. Desai,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[11] H. Joensuu,et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. , 2006, Gastroenterology.
[12] R. Roskoski. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor. , 2005, Biochemical and biophysical research communications.
[13] Adrian A Canutescu,et al. Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling , 2005, Clinical Cancer Research.
[14] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] E. Gaffney,et al. Gastrointestinal stromal tumours , 2003, The British journal of surgery.
[16] S. Hirota,et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.
[17] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[18] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[19] 哲章 亀山,et al. 腹腔鏡下十二指腸局所切除術を施行した十二指腸gastrointestinal stromal tumorの1例 , 2009 .
[20] G. Demetri,et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665 , 2009, Journal of surgical oncology.
[21] P. Loehrer. Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications Through Protein Modeling , 2006 .